These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 39037964)
1. New pharmacodynamic parameters linked with ibrutinib responses in chronic lymphocytic leukemia: Prospective study in real-world patients and mathematical modeling. Cadot S; Audebert C; Dion C; Ken S; Dupré L; Largeaud L; Laurent C; Ysebaert L; Crauste F; Quillet-Mary A PLoS Med; 2024 Jul; 21(7):e1004430. PubMed ID: 39037964 [TBL] [Abstract][Full Text] [Related]
2. Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. O'Brien SM; Jaglowski S; Byrd JC; Bannerji R; Blum KA; Fox CP; Furman RR; Hillmen P; Kipps TJ; Montillo M; Sharman J; Suzuki S; James DF; Chu AD; Coutre SE JAMA Oncol; 2018 May; 4(5):712-716. PubMed ID: 29470582 [TBL] [Abstract][Full Text] [Related]
3. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873 [TBL] [Abstract][Full Text] [Related]
4. Population PK-PD Modeling of Circulating Lymphocyte Dynamics in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment. Gallais F; Ysebaert L; Despas F; De Barros S; Obéric L; Allal B; Chatelut E; White-Koning M Clin Pharmacol Ther; 2021 Jul; 110(1):220-228. PubMed ID: 33539551 [TBL] [Abstract][Full Text] [Related]
5. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. Winqvist M; Asklid A; Andersson PO; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Hansson L; Österborg A Haematologica; 2016 Dec; 101(12):1573-1580. PubMed ID: 27198718 [TBL] [Abstract][Full Text] [Related]
6. Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. Barrientos JC; Burger JA; Byrd JC; Hillmen P; Zhou C; Ninomoto J; James DF; Kipps TJ Leuk Lymphoma; 2019 Apr; 60(4):1000-1005. PubMed ID: 30277101 [TBL] [Abstract][Full Text] [Related]
7. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Thompson PA; O'Brien SM; Wierda WG; Ferrajoli A; Stingo F; Smith SC; Burger JA; Estrov Z; Jain N; Kantarjian HM; Keating MJ Cancer; 2015 Oct; 121(20):3612-21. PubMed ID: 26193999 [TBL] [Abstract][Full Text] [Related]
8. Long-Term Ibrutinib Therapy Reverses CD8 Parry HM; Mirajkar N; Cutmore N; Zuo J; Long H; Kwok M; Oldrieve C; Hudson C; Stankovic T; Paneesha S; Kelly M; Begum J; McSkeane T; Pratt G; Moss P Front Immunol; 2019; 10():2832. PubMed ID: 31921116 [TBL] [Abstract][Full Text] [Related]
9. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Jones JA; Mato AR; Wierda WG; Davids MS; Choi M; Cheson BD; Furman RR; Lamanna N; Barr PM; Zhou L; Chyla B; Salem AH; Verdugo M; Humerickhouse RA; Potluri J; Coutre S; Woyach J; Byrd JC Lancet Oncol; 2018 Jan; 19(1):65-75. PubMed ID: 29246803 [TBL] [Abstract][Full Text] [Related]
11. Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment. Brown JR; Eichhorst B; Hillmen P; Jurczak W; Kaźmierczak M; Lamanna N; O'Brien SM; Tam CS; Qiu L; Zhou K; Simkovic M; Mayer J; Gillespie-Twardy A; Ferrajoli A; Ganly PS; Weinkove R; Grosicki S; Mital A; Robak T; Osterborg A; Yimer HA; Salmi T; Wang MD; Fu L; Li J; Wu K; Cohen A; Shadman M Future Oncol; 2024 Apr; 20(12):717-726. PubMed ID: 39132937 [TBL] [Abstract][Full Text] [Related]
12. Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia. Saleh LM; Wang W; Herman SE; Saba NS; Anastas V; Barber E; Corrigan-Cummins M; Farooqui M; Sun C; Sarasua SM; Zhao Z; Abousamra NK; Elbaz O; Abdelghaffar HA; Wiestner A; Calvo KR Leukemia; 2017 Feb; 31(2):340-349. PubMed ID: 27431016 [TBL] [Abstract][Full Text] [Related]
13. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study. Niemann CU; Herman SE; Maric I; Gomez-Rodriguez J; Biancotto A; Chang BY; Martyr S; Stetler-Stevenson M; Yuan CM; Calvo KR; Braylan RC; Valdez J; Lee YS; Wong DH; Jones J; Sun C; Marti GE; Farooqui MZ; Wiestner A Clin Cancer Res; 2016 Apr; 22(7):1572-82. PubMed ID: 26660519 [TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Jain P; Thompson PA; Keating M; Estrov Z; Ferrajoli A; Jain N; Kantarjian H; Burger JA; O'Brien S; Wierda WG Cancer; 2017 Jun; 123(12):2268-2273. PubMed ID: 28171709 [TBL] [Abstract][Full Text] [Related]
16. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309 [TBL] [Abstract][Full Text] [Related]
17. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Chen LS; Bose P; Cruz ND; Jiang Y; Wu Q; Thompson PA; Feng S; Kroll MH; Qiao W; Huang X; Jain N; Wierda WG; Keating MJ; Gandhi V Blood; 2018 Nov; 132(21):2249-2259. PubMed ID: 30254130 [TBL] [Abstract][Full Text] [Related]
18. Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia. Manukyan G; Turcsanyi P; Mikulkova Z; Gabcova G; Urbanova R; Gajdos P; Smotkova Kraiczova V; Zehnalova S; Papajik T; Kriegova E Leuk Res; 2018 Sep; 72():113-119. PubMed ID: 30149317 [TBL] [Abstract][Full Text] [Related]
19. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia. Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M Front Immunol; 2021; 12():766272. PubMed ID: 34912339 [TBL] [Abstract][Full Text] [Related]
20. Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis. Huang Q; Borra S; Li J; Wang L; Shrestha S; Sundaram M; Janjan N J Manag Care Spec Pharm; 2020 Oct; 26(10):1266-1275. PubMed ID: 32880204 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]